Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Lithotripsy Devices Market Size & Share 2026-2035
Report ID: GMI13314
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Lithotripsy Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Lithotripsy Devices Market Size
The lithotripsy devices market was valued at USD 1.40 billion in 2025, advancing to USD 1.49 billion in 2026, and is projected to grow at a 6.7% CAGR (2026–2035) to reach USD 2.67 billion by 2035.
Lithotripsy Devices Market Key Takeaways
Market Leader: Boston Scientific led with over 30% market share in 2025.
Leading Players: Top 5 players in this market include Boston Scientific, Dornier MedTech, Olympus, EMS Electro Medical, STORZ MEDICAL, which collectively held a market share of 50% in 2025.
The market's evolution is being shaped by a shift from extracorporeal treatment toward intracorporeal laser-based stone management, alongside broader adoption of outpatient procedural pathways. This changes the revenue mix from intermittent capital-system replacement toward recurring demand for laser fibers, scopes, access devices, and related procedure consumables.
GMI Analyst View
Based on our primary engagement with industry stakeholders and our review of key manufacturer revenue reporting, the lithotripsy devices market reached USD 1.30 billion in 2024. We view this pre-base-year performance as evidence that hospital procurement recovery and ambulatory investment were already strengthening before the current forecast period, creating a more durable starting point for technology-led demand.
Lithotripsy Devices Market Trends, Growth Drivers & GMI Forecast Outlook
Stone-disease prevalence, laser-ureteroscopy adoption, and the growing importance of ambulatory care are reshaping purchasing priorities across urology and therapeutic endoscopy. Demand increasingly favors platforms that combine procedural efficiency with consumable attachment, while declining reliance on ESWL tempers replacement opportunities in mature markets.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The clinical burden of stone disease creates demand that is recurrent rather than episodic. A global meta-analysis estimated urolithiasis prevalence at 10.85%, underscoring the size of the patient base that can require repeat imaging, intervention, and follow-up across a lifetime of disease management [4]Vera-Ponce V, et al. "Global prevalence of urolithiasis: a meta-analysis accounting for methodological heterogeneity." frontiersin.org. For providers, this supports investment in equipment that can be deployed repeatedly across renal, ureteral, biliary, and pancreatic stone procedures.
The commercial consequence of ureteroscopy's procedural expansion extends beyond system placement. Laser-based workflows require compatible fibers and accessory devices, and single-use scopes can reduce reprocessing complexity in high-throughput settings. Suppliers with integrated energy, visualization, access, and retrieval offerings are therefore positioned to participate in both capital purchasing cycles and per-procedure spend.
Guideline recognition of thulium fiber laser technology gives clinical teams a clearer basis for incorporating newer laser platforms into flexible ureteroscopy workflows [5]European Association of Urology. "EAU Guidelines on Urolithiasis (2024 Edition)." uroweb.org. That endorsement can shorten evaluation cycles at high-volume institutions, particularly where performance, workflow consistency, and scope compatibility are central to procurement decisions.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
ESWL faces a structural rather than cyclical challenge. Its clinical role narrows where stone characteristics, patient anatomy, or the need for predictable one-session clearance favor ureteroscopy or other endoscopic approaches. The EAU guidelines identify several circumstances in which shock-wave treatment is contraindicated, restricting the patient population suitable for extracorporeal care [5]European Association of Urology. "EAU Guidelines on Urolithiasis (2024 Edition)." uroweb.org.
Capital-allocation decisions also weigh against stand-alone ESWL replacement in facilities expanding outpatient endourology. Flexible scopes, laser systems, and associated single-use devices can support a broader set of procedural workflows, making them more attractive where utilization rates, turnover time, and reimbursement exposure govern purchasing decisions. This leaves extracorporeal device suppliers with a more selective installed-base opportunity.
GMI Analyst View
We see the market's central tension in the contrast between expanding premium intracorporeal demand and the persistent contraction of ESWL's strategic role. The most consequential purchasing decision is no longer simply whether to replace a lithotripsy system, but whether a provider's workflow warrants an integrated laser-ureteroscopy ecosystem with recurring consumable demand.
Lithotripsy Devices Market Segment Analysis
By Device Type
Laser lithotripsy generated USD 700 million in 2025 and is projected to account for 59.7% of market revenue by 2035. The lithotripsy devices market is increasingly defined by laser platforms because they align with flexible ureteroscopy workflows, accommodate complex stone cases, and create recurring demand for compatible fibers and accessories. Thulium fiber and holmium:YAG technologies are strengthening this segment's role in hospital and ambulatory procurement decisions.
ESWL accounted for 35.0% of market revenue in 2025 and is projected to grow at a 4.2% CAGR (2026–2035). Its installed base remains relevant where non-invasive treatment is clinically appropriate or laser capacity is limited, but replacement demand is constrained as providers prioritize workflows that offer greater procedural flexibility and more predictable clearance outcomes.
Electrohydraulic lithotripsy is projected to reach USD 131 million by 2035 and grow at a 4.5% CAGR (2026–2035). Demand is concentrated in specialized biliary and pancreatic applications, where therapeutic endoscopy programs require energy modalities suited to complex ductal stone fragmentation. Its clinical niche supports durable, if measured, equipment demand.
Ultrasonic lithotripsy was valued at USD 84 million in 2025 and is projected to reach USD 145 million by 2035. The modality remains relevant in rigid ureteroscopy and percutaneous procedures, particularly where concurrent fragmentation and aspiration improve workflow efficiency. It also retains value in cost-sensitive settings that seek a less capital-intensive alternative to advanced laser systems.
Mechanical and pneumatic lithotripsy represented 3.0% of market revenue in 2025 and is projected to generate USD 57 million by 2035. These systems remain useful for selected rigid-ureteroscopy cases and in markets with limited laser access, but their long-term position is pressured by the broader migration toward more versatile intracorporeal laser platforms.
By Application
Kidney stone procedures generated USD 700 million in 2025 and are projected to account for 49.1% of market revenue by 2035. Renal stone care is shifting toward flexible ureteroscopy and retrograde intrarenal surgery, increasing the importance of laser energy sources, scope performance, and disposable procedural accessories in the treatment pathway.
Ureteral stone treatment accounted for 34.0% of market revenue in 2025 and is projected to reach USD 954 million by 2035. Ureteroscopy's strong clinical position in symptomatic ureteral calculi supports sustained demand for intracorporeal platforms and access devices, especially in outpatient settings focused on efficient treatment completion.
Pancreatic stone treatment is projected to reach USD 216 million by 2035 and grow at a 6.8% CAGR (2026–2035). Expansion in advanced endoscopic services is widening access to interventions for ductal calculi, supporting demand for electrohydraulic and cholangioscopy-guided laser approaches in chronic pancreatitis management.
Bile duct stone treatment represented 8.0% of market revenue in 2025 and is projected to reach USD 191 million by 2035. Growth is linked to therapeutic endoscopy capacity and the need for more advanced fragmentation options when conventional extraction is unsuccessful or clinically insufficient.
By End Use
Hospitals generated USD 784 million in 2025 and are projected to account for 50.9% of market revenue by 2035. Their procedural role remains indispensable for complex stone burdens, emergency care, and advanced biliary and pancreatic interventions that require multidisciplinary infrastructure, while technology refresh cycles sustain demand for integrated laser and visualization systems.
Ambulatory surgery centers accounted for 34.0% of market revenue in 2025 and are projected to grow at an 8.5% CAGR (2026–2035). Their expansion reflects a care model that values efficient turnover, single-use device availability, and predictable outpatient reimbursement. This setting is becoming a major channel for laser platform placement and recurring fiber and scope utilization.
Other settings, including urology clinics, represented 10.0% of market revenue in 2025 and are projected to reach USD 252 million by 2035. Office-based and specialist outpatient pathways can broaden access to lower-acuity stone management, particularly as non-invasive and lower-complexity treatment options become more practical outside hospital operating environments.
GMI Analyst View
We believe segment leadership will increasingly be determined by the ability to support a complete procedural pathway rather than by fragmentation technology alone. Laser systems, compatible scopes, access products, and consumables reinforce one another commercially, whereas narrower modalities must defend their position through specialized clinical utility, lower acquisition cost, or entrenched installed-base relationships.
Lithotripsy Devices Market Regional Analysis
North America Lithotripsy Devices Market Analysis
North America generated USD 518 million in 2025 and is projected to account for 33.2% of market revenue by 2035. The lithotripsy devices market in the region benefits from established specialist urology networks, extensive outpatient infrastructure, and provider willingness to adopt premium laser-ureteroscopy workflows. Equipment demand is supported by capital refresh cycles and recurring use of fibers, scopes, and access products.
U.S.
The U.S. market generated USD 476 million in 2025 and is projected to reach USD 821 million by 2035. High procedural volumes, broad adoption of outpatient ureteroscopy, and early uptake of advanced laser technologies make the country the region's principal source of device demand and commercial innovation.
Canada
Canada generated USD 42 million in 2025 and is projected to grow at a 5.2% CAGR (2026–2035). Adoption is supported by regional referral centers and public healthcare investment in laser ureteroscopy, although geographic dispersion and provincial purchasing structures can slow the concentration of ambulatory care compared with the U.S.
Europe Lithotripsy Devices Market Analysis
Europe is projected to reach USD 631 million by 2035 and grow at a 5.5% CAGR (2026–2035). The region is characterized by continued migration from ESWL toward laser ureteroscopy, with demand anchored in technology upgrades at established urology centers and gradual capacity development in Southern and Eastern European markets.
Germany
Germany generated USD 84 million in 2025 and is projected to account for 22.0% of European market revenue by 2035. Large academic urology centers, structured hospital funding, and regular capital-equipment evaluation create favorable conditions for adoption of advanced laser platforms and stone-management accessories.
France
France accounted for 16.7% of European market revenue in 2025 and is projected to generate USD 104 million by 2035. The country's movement toward intracorporeal treatment supports laser-system demand, while established endoscopy infrastructure also contributes to opportunities in biliary and pancreatic stone management.
UK
The UK market is projected to reach USD 95 million by 2035 and grow at a 5.5% CAGR (2026–2035). Outpatient urology pathways and flexible-ureteroscopy training capacity support the transition toward laser stone management, while interest in single-use scopes reflects efforts to manage reprocessing requirements and equipment scheduling constraints.
Asia Pacific Lithotripsy Devices Market Analysis
Asia Pacific generated USD 378 million in 2025 and is projected to grow at a 9.2% CAGR (2026–2035). The lithotripsy devices market in Asia Pacific combines a substantial stone-disease burden with rising specialist capacity, hospital investment, and access to endoscopic procedures. China and India are the primary volume engines, while Japan and South Korea support premium device demand through mature clinical infrastructure.
China
China generated USD 154 million in 2025 and is projected to account for 43.0% of Asia Pacific market revenue by 2035. Hospital expansion and wider access to specialty urology services are supporting procurement across public and private provider networks, particularly in higher-tier urban centers.
India
India is projected to reach USD 240 million by 2035 and grow at an 11.0% CAGR (2026–2035). Private-hospital expansion, increasing tertiary-care investment, and unmet need in high-burden geographies are creating a significant runway for procedural growth and broader access to laser-based stone treatment.
Japan
Japan generated USD 77 million in 2025 and is projected to account for 14.8% of Asia Pacific market revenue by 2035. The market's advanced urology infrastructure supports premium technology adoption, although its comparatively mature procedural base limits the pace of volume growth relative to faster-developing regional markets.
South Korea
South Korea generated USD 35 million in 2025 and is projected to grow at a 7.5% CAGR (2026–2035). Specialist infrastructure in major metropolitan areas, growing outpatient activity, and reimbursement pathways for advanced endoscopic interventions support continued market development.
Latin America Lithotripsy Devices Market Analysis
Latin America generated USD 63 million in 2025 and is projected to reach USD 127 million by 2035. Private healthcare investment, distributor-led access to advanced systems, and growing specialist awareness of minimally invasive stone management are supporting demand. ESWL retains a more prominent role than in many developed markets, reflecting capital constraints and uneven access to laser infrastructure.
Brazil
Brazil generated USD 28 million in 2025 and is projected to grow at a 7.8% CAGR (2026–2035). Private hospital investment in major metropolitan areas is the principal source of laser-platform demand, while public-sector purchasing remains more sensitive to capital budgets and procurement timing.
Mexico
Mexico accounted for 33.3% of Latin American market revenue in 2025 and is projected to reach USD 43 million by 2035. Expansion of private hospital networks and endourology services in large urban centers is supporting demand, while public-sector adoption progresses more gradually.
Middle East & Africa Lithotripsy Devices Market Analysis
Middle East & Africa accounted for 4.5% of market revenue in 2025 and is projected to reach USD 139 million by 2035. Government-led healthcare investment, specialist-service development, and the expansion of tertiary hospitals are strengthening demand for advanced lithotripsy systems. Gulf Cooperation Council markets are particularly important for premium laser procurement, while access across Africa remains concentrated in private and specialized facilities.
Saudi Arabia
Saudi Arabia generated USD 21 million in 2025 and is projected to grow at a 9.0% CAGR (2026–2035). Healthcare-capacity investment and the expansion of specialized urology services support the country's transition toward advanced lithotripsy technologies.
UAE
The UAE accounted for 33.3% of Middle East & Africa market revenue in 2025 and is projected to reach USD 50 million by 2035. Well-capitalized private hospitals, international-care positioning, and demand for modern laser systems support its role as a key regional market.
GMI Analyst View
We expect regional opportunity to divide increasingly between mature markets that monetize technology upgrades and developing markets that expand access to specialist procedures. Asia Pacific offers the strongest volume-led runway, while North America and Europe remain strategically important because providers there can adopt integrated platforms with higher realized revenue per procedure.
Lithotripsy Devices Market Share & Competitive Landscape
The lithotripsy devices market is moderately concentrated, with Boston Scientific, Dornier MedTech, Olympus, EMS Electro Medical Systems, and STORZ MEDICAL collectively accounting for approximately 50% of global market revenue in 2025. Market competition is influenced by product portfolio breadth, installed-base relationships, service capabilities, distribution reach, and the ability to generate recurring revenue through disposable products, accessories, and procedural consumables alongside capital equipment sales.
Other key competitors include Becton, Dickinson and Company (BD), Siemens Healthineers, Cook Medical, EDAP TMS, and Richard Wolf, which compete through extensive distribution networks, urology-focused product portfolios, and targeted procedural solutions. Emerging and regional participants, including DirexGroup, ELMED Medical Systems, Inceler Medikal, Medispec, and MTS Medical, continue to strengthen competition in price-sensitive and developing markets where equipment affordability, distributor support, and localized service capabilities play a critical role in purchasing decisions. As the market shifts toward minimally invasive stone management procedures, competitive differentiation is increasingly driven by procedural efficiency, clinical outcomes, service support, and recurring consumable revenue opportunities rather than capital equipment offerings alone.
Recent Industry Developments
In September 2025., Dornier MedTech America announced the U.S. commercial launch of its Hoover Flexible and Navigable Suction Ureteral Access Sheath and AXIS II Slim single-use flexible ureteroscope. The devices extend the company's integrated flexible-ureteroscopy offering and are designed to support suction, irrigation, fragment retrieval, and laser-based stone treatment within a single workflow .
In November 2024, SonoMotion received FDA De Novo clearance for its Stone Clear device, a non-invasive ultrasound-pulse technology intended to facilitate passage of residual kidney stone fragments following lithotripsy. The development broadens the post-procedure stone-management pathway and may create an additional clinic-based option for reducing residual-fragment burden [6]SonoMotion, Inc. "SonoMotion Announces FDA De Novo Clearance for its Stone Clear™ Device." prnewswire.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →